John Buster

Last updated
Dr. John E. Buster John-Buste, MD.jpg
Dr. John E. Buster

John Edmond Buster (born July 18, 1941) is an American physician who, while working at the University of California at Los Angeles School of Medicine, directed the research team that performed the first embryo transfer from one woman to another resulting in a live birth. It was performed at the Harbor-UCLA Medical Center, [1] reported in July 1983, and culminated in the announcement of the birth on February 3, 1984. [2] In the procedure, an embryo that was just beginning to develop was transferred from the woman in whom it had been conceived by artificial insemination to another woman who gave birth to the infant 38 weeks later. The sperm used in the artificial insemination came from the husband of the woman who bore the baby. [3] [4]

Contents

Buster and other members of the UCLA research team were featured in People Magazine , [5] and Time Magazine . [4] Building upon Buster's research, over 200,000 live births resulting from donor embryo transfer have been recorded by the Centers for Disease Control(CDC) [6] in the United States. [7] [8] [9]

Buster continues to practice medicine as a reproductive endocrinologist at Women and Infants' Fertility Center in Providence, Rhode Island. [10]

Education

Buster attended Stanford University for his undergraduate degree and earned both his medical degree and residency training in obstetrics and gynecology from the University of California Los Angeles School of Medicine, where he later completed fellowship training in reproductive endocrinology and infertility. [11]

Career

Buster works in the Division of Reproductive Endocrinology and Infertility at Women & Infants Hospital [12] in Providence, Rhode Island. He is also engaged in private practice and in clinical teaching of Reproductive Endocrinology and Infertility at the Women & Infants/Alpert Medical School (Brown University) [13] fellowship in reproductive endocrinology and infertility. [14]

Research

Buster's research and clinical practice in reproductive medicine include published studies in steroid physiology, pre-implantation embryology, pregnancy loss, and menopausal hormone replacement therapy.[ citation needed ]

Buster authored "Sex and the 50-Something Woman: Strategies for Restoring Satisfaction" in the journal Contemporary Obstetrics and Gynecology. [15] The intent was to explain the various causes of female sexual dysfunction (FSD) and the simple interventions obstetrician/gynecologists and primary care physicians can recommend. The article attracted national interest with stories appearing in local media. [16]

One of Buster's earliest research studies focused on steroid hormone radioimmunoassay (RIA). [17] He reported an RIA for the androgen prohormone, dehydroepiandrosterone sulfate (DHEA-S), the direct measurement of which was shown to be possible in un-extracted serum. [18] Refined versions of his methodology are used in the diagnosis and management of androgen excess disorders in women. [19] He also described for the first time the simultaneous progression of multiple androgen, progestin, and estrogen concentrations in maternal blood throughout all three trimesters of pregnancy and into the onset of labor. [20]

Buster helped develop a testosterone delivery system for women researched by Procter & Gamble. It is marketed in Europe under the brand name Intrinsa. [21] Buster served as lead investigator in another study demonstrating the effectiveness of an estradiol mist, [22] which has pharmacology similar to those of a trans-dermal estrogen patches. Sold in the United States by Perrigo under the name Evamist, it received FDA approval in 2007. [23] Buster's Phase III Study for Evamist was published in the journal, Obstetrics & Gynecology. [24]

In the early 1980s, over a period of 4 years, at the University of California at Los Angeles School of Medicine, [1] Buster and his team developed a technique based on in vivo fertilization and uterine lavage – a method adapted from the commercialization of bovine embryo transfer in the cattle industry – as a means to transfer human blastocysts from fertile woman donors to ovulating or agonadal infertile recipient women. [25] In February 1984, the first live birth, followed 3 months later by a second live birth, resulted from these techniques and was reported by Buster and his team. [26]

Buster updated the uterine lavage technology adapting it to diagnosis and prevention of genetic diseases in embryos. In 2011 Buster founded Previvo Genetics, Inc. He serves on the Board of Directors and Scientific Board. [27]

In April 2019 at the International Federation of Fertility Societies (IFFS)World Congress in Shanghai, China, Buster presented the preliminary results from the first Preimplantation Genetic Testing (PGT) using in vivo Embryos recovered by Uterine Lavage. [28]

In January, 2020, Buster with the Previvo research team reported the first large series (134 hyper stimulation/lavage cycles) describing the successful and safe recovery of 136 in vivo fertilized and matured embryos using in vivo uterine lavage (IVL). [29] For controls, 20 of the lavage subjects also underwent in vitro fertilization (IVF). Most significantly the morphology scores of the IVL blastocysts were significantly higher than the IVF controls.

Awards and honors

Buster received the Legends Award in May 2012 from LA BioMed located at Harbor-UCLA Medical Center. [30] [31]

In June 2014 the American College of Obstetricians and Gynecologists (ACOG) awarded a permanently endowed lectureship, the John E. Buster, M.D. lectureship on cutting edge reproductive medicine. This lecture is given annually. [32] [33]

Publications

Related Research Articles

<span class="mw-page-title-main">Dehydroepiandrosterone</span> Chemical compound

Dehydroepiandrosterone (DHEA), also known as androstenolone, is an endogenous steroid hormone precursor. It is one of the most abundant circulating steroids in humans. DHEA is produced in the adrenal glands, the gonads, and the brain. It functions as a metabolic intermediate in the biosynthesis of the androgen and estrogen sex steroids both in the gonads and in various other tissues. However, DHEA also has a variety of potential biological effects in its own right, binding to an array of nuclear and cell surface receptors, and acting as a neurosteroid and modulator of neurotrophic factor receptors.

<span class="mw-page-title-main">Estrogen</span> Primary female sex hormones

Estrogen or oestrogen is a category of sex hormone responsible for the development and regulation of the female reproductive system and secondary sex characteristics. There are three major endogenous estrogens that have estrogenic hormonal activity: estrone (E1), estradiol (E2), and estriol (E3). Estradiol, an estrane, is the most potent and prevalent. Another estrogen called estetrol (E4) is produced only during pregnancy.

<span class="mw-page-title-main">Estradiol</span> Chemical compound

Estradiol (E2), also spelled oestradiol, is an estrogen steroid hormone and the major female sex hormone. It is involved in the regulation of the estrous and menstrual female reproductive cycles. Estradiol is responsible for the development of female secondary sexual characteristics such as the breasts, widening of the hips and a female-associated pattern of fat distribution. It is also important in the development and maintenance of female reproductive tissues such as the mammary glands, uterus and vagina during puberty, adulthood and pregnancy. It also has important effects in many other tissues including bone, fat, skin, liver, and the brain.

Luteinizing hormone is a hormone produced by gonadotropic cells in the anterior pituitary gland. The production of LH is regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus. In females, an acute rise of LH known as an LH surge, triggers ovulation and development of the corpus luteum. In males, where LH had also been called interstitial cell–stimulating hormone (ICSH), it stimulates Leydig cell production of testosterone. It acts synergistically with follicle-stimulating hormone (FSH).

<span class="mw-page-title-main">Estriol</span> Chemical compound

Estriol (E3), also spelled oestriol, is a steroid, a weak estrogen, and a minor female sex hormone. It is one of three major endogenous estrogens, the others being estradiol and estrone. Levels of estriol in women who are not pregnant are almost undetectable. However, during pregnancy, estriol is synthesized in very high quantities by the placenta and is the most produced estrogen in the body by far, although circulating levels of estriol are similar to those of other estrogens due to a relatively high rate of metabolism and excretion. Relative to estradiol, both estriol and estrone have far weaker activity as estrogens.

<span class="mw-page-title-main">Georgeanna Seegar Jones</span> American gynecologist

Georgeanna Seegar Jones was an American reproductive endocrinologist who with her husband, Howard W. Jones, pioneered in vitro fertilization in the United States.

<span class="mw-page-title-main">Prasterone</span> Medical usage of the prasterone compound

Prasterone, also known as dehydroepiandrosterone (DHEA) and sold under the brand names Intrarosa, Diandrone, and Gynodian Depot among others, is a medication as well as over-the-counter dietary supplement which is used to correct DHEA deficiency due to adrenal insufficiency or old age, as a component of menopausal hormone therapy, to treat painful sexual intercourse due to vaginal atrophy, and to prepare the cervix for childbirth, among other uses. It is taken by mouth, by application to the skin, in through the vagina, or by injection into muscle.

<span class="mw-page-title-main">Dehydroepiandrosterone sulfate</span> Chemical compound

Dehydroepiandrosterone sulfate, abbreviated as DHEA sulfate or DHEA-S, also known as androstenolone sulfate, is an endogenous androstane steroid that is produced by the adrenal cortex. It is the 3β-sulfate ester and a metabolite of dehydroepiandrosterone (DHEA) and circulates in far greater relative concentrations than DHEA. The steroid is hormonally inert and is instead an important neurosteroid and neurotrophin.

<span class="mw-page-title-main">Dydrogesterone</span> Chemical compound

Dydrogesterone, sold under the brand name Duphaston among others, is a progestin medication which is used for a variety of indications, including threatened or recurrent miscarriage during pregnancy, dysfunctional bleeding, infertility due to luteal insufficiency, dysmenorrhea, endometriosis, secondary amenorrhea, irregular cycles, premenstrual syndrome, and as a component of menopausal hormone therapy. It is taken by mouth.

Poor ovarian reserve is a condition of low fertility characterized by 1): low numbers of remaining oocytes in the ovaries or 2) possibly impaired preantral oocyte development or recruitment. Recent research suggests that premature ovarian aging and premature ovarian failure may represent a continuum of premature ovarian senescence. It is usually accompanied by high FSH levels.

<span class="mw-page-title-main">Estrone sulfate</span> Chemical compound

Estrone sulfate, also known as E1S, E1SO4 and estrone 3-sulfate, is a natural, endogenous steroid and an estrogen ester and conjugate.

<span class="mw-page-title-main">Mark Sauer</span> American physician (born 1955)

Mark V. Sauer is an American physician who specializes in reproductive medicine. He is a clinician, researcher and medical educator best known for his work in the development of egg and embryo donation, fertility care of HIV-seropositive patients, and reproductive bioethics. He currently is Professor and Chairman of Obstetrics, Gynecology and Reproductive Sciences at Rutgers Robert Wood Johnson Medical School in New Brunswick, New Jersey. He also serves as the Senior Associate Dean for Women's Health there. Sauer was the Chief of the Division of Reproductive Endocrinology at Columbia University Medical Center in New York City for twenty-one years, where he was also the program and laboratory director of the Center for Women's Reproductive Care, and a tenured professor and vice-chairman in the Department of Obstetrics and Gynecology at the College of Physicians and Surgeons, Columbia University. While at Columbia University he also served on the Medical Ethics Committee of New York Presbyterian-Columbia University Medical Center.

Sandra Ann Carson is an American obstetrician who is the principal innovator of the first artificial human ovary. This innovation was reported in the Journal of Assisted Reproduction and Genetics, and recognized by Time magazine as one of the top 10 medical breakthroughs in 2010.

Alan H. DeCherney is an Obstetrician and Gynecologist who specializes in reproductive endocrinology & infertility. He is experienced in reproductive and endocrinology, infertility, and reproductive genetics.

<span class="mw-page-title-main">17α-Dihydroequilin</span> Chemical compound

17α-Dihydroequilin, or α-dihydroequilin, also known as 7-dehydro-17α-estradiol, as well as estra-1,3,5(10),7-tetraene-3,17α-diol, is a naturally occurring steroidal estrogen found in horses which is closely related to equilin, equilenin, and 17α-estradiol. The compound, as the 3-sulfate ester sodium salt, is present in conjugated estrogens (Premarin), a pharmaceutical extract of the urine of pregnant mares, and is the third highest quantity constituent in the formulation (13.8%). The compound has been studied clinically.

<span class="mw-page-title-main">Estradiol sulfate</span> Chemical compound

Estradiol sulfate (E2S), or 17β-estradiol 3-sulfate, is a natural, endogenous steroid and an estrogen ester. E2S itself is biologically inactive, but it can be converted by steroid sulfatase into estradiol, which is a potent estrogen. Simultaneously, estrogen sulfotransferases convert estradiol to E2S, resulting in an equilibrium between the two steroids in various tissues. Estrone and E2S are the two immediate metabolic sources of estradiol. E2S can also be metabolized into estrone sulfate (E1S), which in turn can be converted into estrone and estradiol. Circulating concentrations of E2S are much lower than those of E1S. High concentrations of E2S are present in breast tissue, and E2S has been implicated in the biology of breast cancer via serving as an active reservoir of estradiol.

<span class="mw-page-title-main">17β-Dihydroequilenin</span> Chemical compound

17β-Dihydroequilenin, or β-dihydroequilenin, also known as δ6,8-17β-estradiol or 6,8-didehydro-17β-estradiol, as well as estra-1,3,5(10),6,8-pentaen-3,17β-diol, is a naturally occurring steroidal estrogen found in horses which is closely related to equilin, equilenin, and estradiol, and, as the 3-sulfate ester sodium salt, is a minor constituent (0.5%) of conjugated estrogens (Premarin). 17β-Dihydroequilenin has unexpectedly shown a selective estrogen receptor modulator (SERM)-like profile of estrogenic activity in studies with monkeys, in which beneficial effects on bone and the cardiovascular system were noted but proliferative responses in breast and endometrium were not observed.

<span class="mw-page-title-main">16α-Hydroxy-DHEA sulfate</span> Chemical compound

16α-Hydroxydehydroepiandrosterone sulfate (16α-OH-DHEA-S), also known as 16α-hydroxy-17-oxoandrost-5-en-3β-yl sulfate, is an endogenous, naturally occurring steroid and a metabolic intermediate in the production of estriol from dehydroepiandrosterone (DHEA) during pregnancy. It is the C3β sulfate ester of 16α-hydroxy-DHEA.

<span class="mw-page-title-main">15α-Hydroxy-DHEA sulfate</span> Chemical compound

15α-Hydroxydehydroepiandrosterone sulfate, abbreviated as 15α-hydroxy-DHEA sulfate or 15α-OH-DHEA-S, also known as 15α-hydroxy-17-oxoandrost-5-en-3β-yl sulfate, is an endogenous, naturally occurring steroid and a metabolic intermediate in the production of estetrol from dehydroepiandrosterone (DHEA) during pregnancy. It is the C3β sulfate ester of 15α-hydroxy-DHEA.

Norbert Gleicher is an American obstetrician-gynecologist active in obstetrical practice, in vitro fertilization, reproductive endocrinology, and reproductive immunology. He is a fellow of the American College of Obstetricians and Gynecologists (FACOG) and the American College of Surgeons (ACS) and currently serves as president, medical director and chief scientist of the Center for Human Reproduction (CHR) in New York City, a clinical fertility center that he founded in 1981. Simultaneously, he is President of the Foundation for Reproductive Medicine, a not-for-profit research foundation. Gleicher maintains additional academic appointments at Rockefeller University, and Medical University of Vienna.

References

  1. 1 2 "Research Accomplishments". Harbor-UCLA Medical Center. Archived from the original on 3 March 2016. Retrieved 27 June 2014.
  2. ↑ Blakeslee, Sandra (3 February 1984). "Infertile woman has baby through embryo transfer". New York Times. Retrieved 27 June 2014.
  3. ↑ Friedrich, Otto (10 September 1984). "Medicine: A legal, moral, social nightmare". Time. Archived from the original on February 16, 2009. Retrieved 27 June 2014.
  4. 1 2 Wallis, Claudia (1984-09-10). "The New Origins of Life". Time. Archived from the original on January 14, 2005. Retrieved 27 June 2014.
  5. ↑ Jares, Sue Ellen (1983-08-08). "A UCLA Doctor, First to Transplant Human Embryos, Offers Hope to Infertile Women". People. 20 (6). Retrieved 27 June 2014.
  6. ↑ "Assisted Reproductive Technology (ART)". Centers for Disease Control. Retrieved 27 June 2014.
  7. ↑ "Dead URL" (PDF). Sexuality, Reproduction and Menopause magazine. Archived from the original (PDF) on 2009-02-20.
  8. ↑ "Dead URL". Sexuality, Reproduction and Menopause magazine. Archived from the original on 2007-10-08.
  9. ↑ Mendell, Patricia; Benward, Jean. "Talking with Children About Ovum Donation". American Fertility Association - Infertility and Family Building. Archived from the original on 2013-05-11. Retrieved 27 June 2014.
  10. ↑ "John Buster, MD | Women & Infants' Fertility Center". Women & Infants' Fertility Center. Retrieved 2017-04-27.
  11. ↑ "Reproductive Endocrinology and Infertility Center". Tufts Medical Center. Retrieved 27 June 2014.
  12. ↑ England, Care New. "John Buster". www.womenandinfants.org. Retrieved 2016-07-27.
  13. ↑ "Buster, John". vivo.brown.edu. Retrieved 2016-07-27.
  14. ↑ "Brown University Fellowship in REI". Alpert Medical School of Brown University. Retrieved 27 June 2014.
  15. ↑ Buster, John (August 2012). "Sex and the 50-Something Woman". Contemporary OB/GYN. 57 (8): 32–39. Retrieved 27 June 2014.
  16. ↑ Reinsel Cotter, Pamela (2012). "When desire wanes". Providence Journal. Providence RI. Archived from the original on 2013-01-30. Retrieved 27 June 2014.
  17. ↑ Buster, John E.; Chang, R. Jeffrey; Preston, Dale L.; Elashoff, Robert M.; Cousins, Larry M.; Abraham, GUY E.; Hobel, Calvin J.; Marshall, John R. (1979). "Interrelationships of Circulating Maternal Steroid Concentrations in Third Trimester Pregnancies. II. C18and C19Steroids: Estradiol, Estriol, Dehydroepiandrosterone, Dehydroepiandrosterone Sulfate, Δ5-Androstenediol, Δ4-Androstenedione, Testosterone, and Dihydrotestosterone". The Journal of Clinical Endocrinology & Metabolism. 48 (1): 139–142. doi:10.1210/jcem-48-1-139. PMID   154525.
  18. ↑ Buster, John E.; Abraham, Guy E. (5 December 2006). "Radioimmunoassay of Plasma Dehydroepiandrosterone Sulfate". Analytical Letters. 5 (8): 543–551. doi:10.1080/00032717208062119.
  19. ↑ Abraham, G. E.; Buster, J. E.; Samojlik, E.; Garza, R.; Hillan, B. (February 1974). "Comparison Between Four Radioimmunoassays for Plasma Estriol". Analytical Letters. 7 (2): 119–123. doi:10.1080/00032717408058745.
  20. ↑ Buster, JE; Chang, RJ; Preston, DL; Elashoff, RM; Cousins, LM; Abraham, GE; Hobel, CJ; Marshall, JR (January 1979). "Interrelationships of circulating maternal steroid concentrations in third trimester pregnancies. I. C21 steroids: progesterone, 16 alpha-hydroxyprogesterone, 17 alpha-hydroxyprogesterone, 20 alpha-dihydroprogesterone, delta 5-pregnenolone, delta 5-pregnenolone sulfate, and 17-hydroxy delta 5-pregnenolone". The Journal of Clinical Endocrinology and Metabolism. 48 (1): 133–8. doi: 10.1210/jcem-48-1-133 . PMID   422695.
  21. ↑ "Should testosterone therapy be used to treat HSDD in reproductive-aged women?".
  22. ↑ Buster, John E (January 2009). "Low-Dose Estradiol Spray: a Novel Treatment for Vasomotor Instability in Postmenopausal Women". Women's Health. 5 (1): 23–28. doi: 10.2217/17455057.5.1.23 . PMID   19102636.
  23. ↑ "FDA Approves Spray-On Estrogen to Treat Menopause". Fox News. 2008-06-02. Retrieved 27 June 2014.
  24. ↑ Buster, John E.; Koltun, William D.; Pascual, Maria Luz G.; Day, Wesley W.; Peterson, Craig (June 2008). "Low-Dose Estradiol Spray to Treat Vasomotor Symptoms". Obstetrics & Gynecology. 111 (6): 1343–1351. doi:10.1097/AOG.0b013e318175d162. PMID   18515518. S2CID   12333843.
  25. ↑ Sauer, Mark V, ed. (1998). "1". Principles of Oocyte and Embryo Donation. New York: Springer-Verlag. pp. 1–10. ISBN   0387949607 . Retrieved 27 June 2014.
  26. ↑ "Embryo-Transfer Baby Born". The New York Times. 1984-03-25. Retrieved 27 June 2014.
  27. ↑ "Previvo Genetics - A New Choice in Pre-Implantation Genetic Diagnosis". previvo.com. Retrieved 2016-07-27.{{cite web}}: Check |url= value (help)
  28. ↑ "International Federation of Fertility Societies (IFFS)".
  29. ↑ Munné, Santiago; Nakajima, Steven T.; Najmabadi, Sam; Sauer, Mark V.; Angle, Marlane J.; Rivas, José L.; Mendieta, Laura V.; MacAso, Thelma M.; Sawarkar, Sarthak; Nadal, Alexander; Choudhary, Kajal; Nezhat, Camran; Carson, Sandra A.; Buster, John E. (January 2020). "Human Reproduction (ESHRE)". Human Reproduction. 35 (1): 70–80. doi:10.1093/humrep/dez242. PMC   6993848 . PMID   31886877.
  30. ↑ "Medical researchers honored at LA Biomeds legends event". Daily Breeze. 2012-05-10. Retrieved 27 June 2014.
  31. ↑ "Physician to be honored as Legend" (Press release). Women & Infants Hospital of Rhode Island. Retrieved 27 June 2014.
  32. ↑ "Endowments - ACOG". www.acog.org. Retrieved 2016-07-27.
  33. ↑ "Subspecialty Sessions - ACOG". www.acog.org. Archived from the original on 2016-07-20. Retrieved 2016-07-27.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.